Neoadjuvant Therapy With Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

A 68-year-old man with muscle-invasive bladder cancer (MIBC) and severe renal insufficiency, who was ineligible for cisplatin-based treatment, was successfully treated with neoadjuvant therapy using gemcitabine and Disitamab Vedotin (DV). The patient received three cycles of gemcitabine 1600 mg and DV 120 mg intravenously every three weeks. Imaging results showed a significant reduction in lesions, indicating a radiological partial response. Throughout the treatment, no significant adverse side effects were observed, making this combination a viable alternative for patients unable to tolerate platinum-based regimens.